Pediococcus acidilactici CECT9879 (pA1c) Counteracts the Effect of a High-Glucose Exposure in C. elegans by Affecting the Insulin Signaling Pathway (IIS)
- 2022-02-28
- International Journal of Molecular Sciences 23(5)
- Deyan Yavorov-Dayliev
- F. Milagro
- J. Ayo
- M. Oneca
- P. Aranaz
- PubMed: 35269839
- DOI: 10.3390/ijms23052689
Abstract
The increasing prevalence of metabolic syndrome-related diseases, including type-2 diabetes and obesity, makes it urgent to develop new alternative therapies, such as probiotics. In this study, we have used Caenorhabditis elegans under a high-glucose condition as a model to examine the potential probiotic activities of Pediococcusacidilactici CECT9879 (pA1c). The supplementation with pA1c reduced C. elegans fat accumulation in a nematode growth medium (NGM) and in a high-glucose (10 mM) NGM medium. Moreover, treatment with pA1c counteracted the effect of the high glucose by reducing reactive oxygen species by 20%, retarding the aging process and extending the nematode median survival (>2 days in comparison with untreated control worms). Gene expression analyses demonstrated that the probiotic metabolic syndrome-alleviating activities were mediated by modulation of the insulin/IGF-1 signaling pathway (IIS) through the reversion of the glucose-nuclear-localization of daf-16 and the overexpression of ins-6 and daf-16 mediators, increased expression of fatty acid (FA) peroxisomal β-oxidation genes, and downregulation of FA biosynthesis key genes. Taken together, our data suggest that pA1c could be considered a potential probiotic strain for the prevention of the metabolic syndrome-related disturbances and highlight the use of C. elegans as an appropriate in vivo model for the study of the mechanisms underlying these diseases.
Keywords: Caenorhabditis elegans; daf-16; diabetes; insulin-signaling-pathway; obesity; probiotic; β-oxidation.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Pediococcus acidilactici | Delayed Skin Aging | Beneficial | Moderate |
Pediococcus acidilactici | Increased Survival Time | Beneficial | Moderate |
Pediococcus acidilactici | Reduced Hepatic Fat Accumulation | Beneficial | Moderate |
Pediococcus acidilactici | Reduced Intracellular Reactive Oxygen Species Levels | Beneficial | Small |
Pediococcus acidilactici KABP™-021 | Delayed Skin Aging | Beneficial | Moderate |
Pediococcus acidilactici KABP™-021 | Improved Insulin Sensitivity | Beneficial | Large |
Pediococcus acidilactici KABP™-021 | Increased Fatty Acid Oxidation | Beneficial | Moderate |
Pediococcus acidilactici KABP™-021 | Increased Survival Time | Beneficial | Moderate |
Pediococcus acidilactici KABP™-021 | Reduced Fatty Acid Synthesis | Beneficial | Moderate |
Pediococcus acidilactici KABP™-021 | Reduced Hepatic Fat Accumulation | Beneficial | Moderate |
Pediococcus acidilactici KABP™-021 | Reduced Intracellular Reactive Oxygen Species Levels | Beneficial | Small |
Pediococcus acidilactici MAK92P26A | Delayed Skin Aging | Beneficial | Moderate |
Pediococcus acidilactici MAK92P26A | Improved Insulin Sensitivity | Beneficial | Large |
Pediococcus acidilactici MAK92P26A | Increased Survival Time | Beneficial | Moderate |
Pediococcus acidilactici MAK92P26A | Reduced Hepatic Fat Accumulation | Beneficial | Moderate |
Pediococcus acidilactici MAK92P26A | Reduced Intracellular Reactive Oxygen Species Levels | Beneficial | Small |
Pediococcus acidilactici VPro29 | Improved Fatty Acid Oxidation | Beneficial | Moderate |
Pediococcus acidilactici VPro29 | Improved Insulin Sensitivity | Beneficial | Large |
Pediococcus acidilactici VPro29 | Increased Survival Time | Beneficial | Moderate |
Pediococcus acidilactici VPro29 | Reduced Hepatic Fat Accumulation | Beneficial | Moderate |
Pediococcus acidilactici VPro29 | Reduced Intracellular Reactive Oxygen Species Levels | Beneficial | Small |